BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 7976857)

  • 1. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
    Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
    Ratliff TL; Palmer JO; McGarr JA; Brown EJ
    Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of intravesical BCG for bladder cancer.
    Ratliff TL
    Prog Clin Biol Res; 1989; 310():107-22. PubMed ID: 2672010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
    Zlotta AR; Drowart A; Huygen K; De Bruyn J; Shekarsarai H; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Mascart F; Simon J; Schulman CC; Van Vooren JP
    Clin Exp Immunol; 1997 Jul; 109(1):157-65. PubMed ID: 9218839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.
    de Boer EC; Steerenberg PA; van der Meijden AP; van Klingeren B; de Jong WH; Debruyne FM; Ruitenberg EJ
    Prog Clin Biol Res; 1992; 378():81-93. PubMed ID: 1301589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer.
    Andrade PM; Chade DC; Borra RC; Nascimento IP; Villanova FE; Leite LC; Andrade E; Srougi M
    Urol Oncol; 2010; 28(5):520-5. PubMed ID: 19272796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
    Winters WD; Lamm DL
    Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.
    van der Meijden AP; Steerenberg PA; van Hoogstraaten IM; Kerckhaert JA; Schreinemachers LM; Harthoorn-Lasthuizen EJ; Hagenaars AM; de Jong WH; Debruijne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1989; 28(4):287-95. PubMed ID: 2784716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin.
    Bilen CY; Inci K; Erkan I; Ozen H
    J Urol; 2003 May; 169(5):1702-5. PubMed ID: 12686812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
    Zlotta AR; van Vooren JP; Huygen K; Drowart A; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Simon J; Schulman CC
    Eur Urol; 2000 Apr; 37(4):470-7. PubMed ID: 10765079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.
    De Boer EC; De Jong WH; Steerenberg PA; Van der Meijden AP; Aarden LA; Debruyne FM; Ruitenberg EJ
    In Vivo; 1991; 5(6):671-7. PubMed ID: 1810454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
    Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
    Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways.
    Hudson MA; Brown EJ; Ritchey JK; Ratliff TL
    Cancer Res; 1991 Jul; 51(14):3726-32. PubMed ID: 2065329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.